Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Obstetrics/Gynecology (Women’s Health) | Family Medicine | Gastroenterology
Cervical Cancer Clinical Trials
A listing of Cervical Cancer medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : UAB Comprehensive Cancer Center
Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
Arizona
Phoenix :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Tucson :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
California
Rolling Hills Estates : Peninsula Research Associates
HPV Cervical Cancer Vaccine Study
View More »
Colton :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
La Mesa :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Los Angeles :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Colorado
Lakewood :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
District of Columbia
Washington : Childrens National Medical Center
Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?
Washington : Georgetown University Hospital
Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?
Florida
Boynton Beach :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Fort Lauderdale :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Miami : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Sarasota :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Georgia
Hawaii
Honolulu : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Iowa
Iowa City : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Iowa City : GSK Investigational Site
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Kansas
Wichita : GSK Investigational Site
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Maryland
Baltimore :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Michigan
Saginaw :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Montana
Missoula :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
New Mexico
Albuquerque : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
New York
Bronx :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Port Jefferson :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
North Carolina
Chapel Hill : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Raleigh :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Winston-Salem :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Ohio
Athens :
Community Awareness, Resources and Education (CARE): Project 3
Columbus :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Gallipolis :
Community Awareness, Resources and Education (CARE): Project 3
Logan :
Community Awareness, Resources and Education (CARE): Project 3
Pomeroy :
Community Awareness, Resources and Education (CARE): Project 3
Oklahoma
Oklahoma city :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Oklahoma City : Oklahoma University Cancer Institute
Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
Oregon
Eugene :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Pennsylvania
Philadelphia :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
South Carolina
Myrtle Beach :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Texas
Houston : UT MD Anderson Cancer Center
Chemoradiation-Induced Nausea and Emesis: Quality of Life
Utah
Murray :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Pleasant Grove :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Sandy :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Virginia
Richmond :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Richmond : Virginia Commonwealth University Massey Cancer Center
Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer
Washington
Renton :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Spokane :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Wenatchee : GSK Investigational Site
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Australia
Perth : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Victoria :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Brazil
Campinas : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Campinas : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Curitiba : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Porto Alegre : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Porto Alegre : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Canada
Beauport : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Edmonton : GSK Investigational Site
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Halifax : GSK Investigational Site
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Montreal :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Sherbrooke : GSK Investigational Site
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
View More »
Truro : GSK Investigational Site
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Vancouver : GSK Investigational Site
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Vancouver B.C. :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
China
Beijing : Cancer Institute ＆ Hospital Chinese Academy of Medical Sciences
Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine
Nanjing : Jiangsu Provincial Centre for Disease Control and Prevention
Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine
Croatia
Zagreb : University Hospital for Infectious Diseases, Croatia
Distribution of Human Papillomavirus (HPV) Genotypes in Patients With Cervical Cancer From Croatia
Denmark
Hvidovre : Hvidovre Hospital
European Clinical Evaluation of the BD HPV Assay on the BD Viper LT System
Estonia
Tallinn :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Tartu :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Finland
Helsinki : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Jyvaskyla : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Kotka : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Kouvola : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Kuopio : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
View More »
Lahti : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Lappeenranta : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Mikkeli : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Oulu : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Pori : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Rauma : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Seinajoki : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Tampere : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Turku : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Vaasa : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Georgia
Batumi :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Tbilisi :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Germany
Berlin : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Hamburg : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Karlsruhe : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Muenchen : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Ravensburg : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
View More »
Wuerzburg : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
India
Bangalore :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Chennai : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Jaipur :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Kolkata :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Kolkata : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
View More »
Mumbai : Tata Memorial Hospital
A Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix
Mumbai : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
New Delhi :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Pune :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Pune : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Italy
Milan : European Institute of Oncology
European Clinical Evaluation of the BD HPV Assay on the BD Viper LT System
Modena : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Korea, Republic of
Seoul :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Seoul : Asan Medical Center
Efficacy and Safety Study of Concurrent Chemoradiation Therapy to Treat Locally Advanced Cervical Cancer
Seoul : Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center
Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer
Netherlands
Amsterdam : GSK Investigational Site
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Amsterdam : Research Site
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
Philippines
Cavite : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Cebu : Minglanilla
Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention
Laguna : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Las Pinas City : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Los Banos, Laguna : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
View More »
Makati City : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Manila : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Quezon : Pagbilao Health Center
Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention
Quezon : Los Banos
Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention
Portugal
Almada : GSK Investigational Site
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Coimbra : GSK Investigational Site
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Lisboa : GSK Investigational Site
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Setúbal : GSK Investigational Site
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Puerto Rico
San Juan :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
South Africa
Bloemfontein :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Cape Town :
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Spain
L'Hospitalet de Llobregat : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Móstoles/Madrid : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Taiwan
Taipei : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Thailand
Bangkok : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Bangkok : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Chiangmai : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Khon Kaen : GSK Investigational Site
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Nakhon Si Thammarat : Ban Pak Poon Health Center
Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention
View More »
Nakhon Si Thammarat : Pak-Panung District Health Center
Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention
Nakhon Si Thammarat : Maharat Nakhonsithammarat Primary Care Unit
Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention
Nakhon Si Thammarat : Health promotion Clinic Number 11
Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention
Nakhon Si Thammarat, Nakornsri : Ban Mai Daeng
Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention
Nakhon Si Thammarat, Nakornsri : Ban Pai Ta Health Center
Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention
United Kingdom
Cambridge : Cambridge University Hospitals NHS Foundation Trust
HYPAZ: Hypertension Induced by Pazopanib
London : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Manchester : GSK Investigational Site
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Manchester : GSK Investigational Site
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Manchester : Research Site
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
View More »
Sutton : Research Site
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
